Targeting Receptor Kinases in Colorectal Cancer
نویسندگان
چکیده
منابع مشابه
miR-506 inhibits cell proliferation and invasion by targeting TET family in colorectal cancer
Objective(s): Ten-eleven translocation (TET) family members have been shown to be involved in the development of many tumors. However, the biological role of the TET family and its mechanism of action in colorectal carcinogenesis and progression remain poorly understood. Materials and Methods:We measured the expression levels of TET family members in colorectal cancer (CRC) specimens, in the c...
متن کاملTargeting Axl and Mer kinases in cancer.
Receptor tyrosine kinases (RTK) are cell-surface transmembrane receptors that contain regulated kinase activity within their cytoplasmic domain and play an important role in signal transduction in both normal and malignant cells. The mammalian TAM RTK family includes 3 closely related members: Tyro-3, Axl, and Mer. Overexpression or ectopic expression of the TAM receptors has been detected in a...
متن کاملTargeting mitotic kinases for anti - cancer treatment
Cancer cells proliferate unlimitedly. Therefore, targeting the proliferative capacity of cancer is one of the smartest ways to treat cancer. In this vein, understanding the basis of mitosis is essential for the advanced treatment of cancer, let alone its importance in basic biology. Indeed, recent progress in anti-cancer strategy has come from the development of a group of inhibitors targeting ...
متن کاملTargeting Colorectal Cancer Cell Lines Using Nanobodies; AgSK1as a Potential Target
Background: Colorectal cancer is the third most common type of aggressive cancers. Chemotherapy, surgery,and radiotherapy are the common therapeutic options for treating this cancer. Due to the adverse side-eff ects of these methods, immunotherapy is considered as an appropriate alternative therapeutic option. Treatment through the application of monoclonal antibodies is considered as a n...
متن کاملTargeting mutant BRAF in colorectal cancer
Background Mutations in BRAF V600E oncogene (BRAFMT) occurs in 8-15% of colorectal cancer (CRC) patients1. This mutation constitutively activates MAPK signalling, resulting in a proliferative and survival advantage for the tumour cells and oncogenic BRAF status has been linked with poor prognosis2. Despite introduction of the BRAFMT specific inhibitor Vemurafenib in metastatic melanoma3, there ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancers
سال: 2019
ISSN: 2072-6694
DOI: 10.3390/cancers11040433